Press Releases

Date Title and Summary Additional Formats
Toggle Summary Seattle Genetics Added to Russell 2000 and Russell 3000 Stock Indexes
Bothell, WA – July 10, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the Company has been added to the Russell 2000® and Russell 3000® stock indexes. These Russell Indexes, issued by the Frank Russell Company, are adjusted annually based on market capitalization as of May 31st.
View HTML
Toggle Summary Seattle Genetics Names Morris Rosenberg Vice President, Development
Company expands its product development and clinical manufacturing initiatives Bothell, WA – July 10, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today the appointment of Morris Z. Rosenberg as Vice President, Development. Dr. Rosenberg will be responsible for overseeing all aspects of
View HTML
Toggle Summary Seattle Genetics and Eos Biotechnology Collaborate To Develop Next Generation Antibody-Drug Conjugates For Cancer Therapy
Bothell, WA and South San Francisco, CA – June 5, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) and Eos Biotechnology, Inc. announced today a collaboration to use Seattle Genetics’ toxic payload technology with Eos’ proprietary monoclonal antibodies directed against novel cancer targets derived from
View HTML
Toggle Summary Seattle Genetics Appoints New Members to its Board of Directors and Scientific Advisory Board
Immunex’s Executive Vice President Douglas E. Williams, Ph.D. Added to Board of Directors Noted Cancer Expert Dan L. Longo, M.D. Added to Scientific Advisory Board Bothell, WA – May 17, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today the appointment of new members to both its Board of
View HTML
Toggle Summary Seattle Genetics Scheduled at CIBC World Markets Bio-Technology Conference
Bothell, WA — May 1, 2001 — Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Scientific Officer, will speak at the CIBC World Markets First Annual Bio-Technology Conference on May 2, 2001 at 10:25 a.m. Eastern Time.
View HTML
Toggle Summary Seattle Genetics Reports First Quarter Results
Bothell, WA — April 24, 2001— Seattle Genetics, Inc. (Nasdaq: SGEN) today reported results for its first quarter ended March 31, 2001. Net loss for the quarter was $4.2 million, or $0.46 per share, compared to a net loss of $0.9 million, or $.30 per share for the same period in 2000.
View HTML
Toggle Summary Seattle Genetics Announces Initial Public Offering
Bothell, WA – March 7, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today the pricing of its initial public offering of 7,000,000 shares of common stock at $7.00 per share. The offering includes a $2 million investment, or 285,714 shares, purchased directly by Genentech, Inc.
View HTML
Toggle Summary Seattle Genetics and Medarex Establish Alliance to Develop Human Antibody Therapeutics
Medarex to invest $2 million in Seattle Genetics Bothell, WA and Princeton, NJ: February 7, 2001— Seattle Genetics, Inc. and Medarex, Inc. (Nasdaq: MEDX) today announced the formation of a strategic alliance through which the two companies expect to utilize Medarex's UltiMAb™ Human Antibody
View HTML
Toggle Summary Seattle Genetics Initiates Phase II Clinical Trial in Prostate Cancer
Bothell, WA – November 30, 2000 – Seattle Genetics, Inc. announced the initiation of a phase II clinical trial with one of its lead drug candidates, SGN-15. The trial will evaluate the monoclonal antibody-drug conjugate SGN-15 in combination with the chemotherapeutic drug Taxotere® for patients
View HTML
Toggle Summary Seattle Genetics Files For Initial Public Offering of Common Stock
Bothell, WA - November 20, 2000 - Seattle Genetics, Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission for an initial public offering of its common stock. All of the shares to be registered will be offered by Seattle Genetics. J.P.
View HTML